Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, May 19, 2023.
In a significant development, the FDA has cleared Abbott’s insertable cardiac monitor, marking an important advancement in cardiac care. This device offers healthcare professionals a valuable tool for long-term monitoring of patients’ heart rhythms, enabling early detection and timely intervention. Fast Five hosts Sean Whooley and Danielle Kirsh detail what the device does and how optimistic executives at the company are.
Paradromics has raised $33 million in funding. This substantial investment reflects the growing interest and potential of brain-computer interfaces in revolutionizing how we interact with technology and understand the human brain. Whooley and Kirsh discuss how the technology works and some of the other major players in the space.
The FDA has approved MicroPort’s next-generation of pacemakers. Whooley explains what sets these devices apart from previous iterations, what they do and how executives are looking to further advance cardiac rhythm management.
A recent study has provided support for LifeScan’s smart blood glucose meter. The study’s findings validate the effectiveness and reliability of the smart meter. Whooley goes through the results of the study and what this could mean for people living with diabetes.
Biosense Webster, a subsidiary of Johnson & Johnson, has welcomed a new president to lead the company. This leadership change reflects Biosense Webster’s ongoing commitment to driving innovation in the field of electrophysiology and advancing treatment options for patients with cardiac arrhythmias. The Fast Five hosts discuss the new appointment and her previous leadership roles.
Subscribe to the Fast Five daily news podcast on your preferred listening platform. If you’re on a desktop computer, scan the QR code below with your smartphone to easily access the podcast on your mobile device.